Smith & Nephew Rating Reiterated by Deutsche Bank (SN)
Smith & Nephew (LON:SN)‘s stock had its “hold” rating reiterated by equities researchers at Deutsche Bank in a research report issued on Thursday, Analyst Ratings Network.com reports. They currently have a GBX 650 ($10.67) price objective on the stock. Deutsche Bank’s price target points to a potential downside of 27.46% from the stock’s previous close.
SN has been the subject of a number of other recent research reports. Analysts at Galvan Research reiterated a “buy” rating on shares of Smith & Nephew in a research note to investors on Wednesday. They now have a GBX 930 ($15.27) price target on the stock. Separately, analysts at Goldman Sachs Group Inc. downgraded shares of Smith & Nephew to a “sell” rating in a research note to investors on Wednesday. They now have a GBX 720 ($11.82) price target on the stock, down previously from GBX 780 ($12.80). Finally, analysts at Citigroup Inc. raised their price target on shares of Smith & Nephew from GBX 830 ($13.62) to GBX 870 ($14.28) in a research note to investors on Monday. They now have a “neutral” rating on the stock. Three research analysts have rated the stock with a sell rating, eleven have issued a hold rating and five have given a buy rating to the company. Smith & Nephew has an average rating of “Hold” and a consensus target price of GBX 809.82 ($13.29).
Shares of Smith & Nephew (LON:SN) traded up 1.07% during mid-day trading on Thursday, hitting GBX 896.00. 3,807,517 shares of the company’s stock traded hands. Smith & Nephew has a one year low of GBX 692.592 and a one year high of GBX 897.00. The stock has a 50-day moving average of GBX 860.3 and a 200-day moving average of GBX 804.. The company’s market cap is £8.055 billion.
Smith & Nephew plc is a global medical devices business operating in the markets for orthopaedic reconstruction and trauma, endoscopy (LON:SN) and advanced wound management.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.